NewsBenzingaLos planes de Benjamin Netanyahu para burlar posibles sanciones con criptomonedas son calificados de destructivos por un rival: ha “perdido el rumbo...” Los planes de Benjamin Netanyahu para burlar posibles sanciones con criptomonedas son calificados de destructivos por un rival: ha “perdido el rumbo...” Benzinga 2026.10.26 05:00 (GMT+0) Open on Benzinga Other news Reported Friday, Travere Says PROTECT Biomarker Data Add To Superior Proteinuria Reduction, Slower Kidney Function Decline Versus Irbesartan, Supporting FILSPARI As Non-Immunosuppressive, Kidney-Targeted, Foundational First-Line Treatment For IgA... Reported Saturday, Lilly Presented First Phase 1 Data For Sofe-M Plus Bevacizumab In Platinum-Sensitive Ovarian Cancer: 79% Confirmed Objective Response Rate, 100% Disease Control Rate, Activity Across FRα Expression Levels Reported Saturday, Immatics Reports IMA203CD8 Cell Therapy 51% ORR, 41% cORR Across Multiple Solid Tumors With Manageable Safety; IMA402 Bispecific Shows 32% cORR In PRAME-High Melanoma, Favorable Safety Profile Reported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply AstraZeneca Announced Saturday,Perioperative IMFINZI Plus Neoadjuvant Enfortumab Vedotin Cuts Recurrence Risk 49%, Death Risk 42% Versus Standard Of Care In Muscle-Invasive Bladder Cancer Patients Ineligible For Or Refusing Cisplatin, VOLGA Phase III Marjorie Taylor Greene Says Health Insurance Is ‘an Unaffordable Disaster’ and Republicans ‘Have Not Even Attempted to Fix It’
Reported Friday, Travere Says PROTECT Biomarker Data Add To Superior Proteinuria Reduction, Slower Kidney Function Decline Versus Irbesartan, Supporting FILSPARI As Non-Immunosuppressive, Kidney-Targeted, Foundational First-Line Treatment For IgA...
Reported Saturday, Lilly Presented First Phase 1 Data For Sofe-M Plus Bevacizumab In Platinum-Sensitive Ovarian Cancer: 79% Confirmed Objective Response Rate, 100% Disease Control Rate, Activity Across FRα Expression Levels
Reported Saturday, Immatics Reports IMA203CD8 Cell Therapy 51% ORR, 41% cORR Across Multiple Solid Tumors With Manageable Safety; IMA402 Bispecific Shows 32% cORR In PRAME-High Melanoma, Favorable Safety Profile
Reported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply
AstraZeneca Announced Saturday,Perioperative IMFINZI Plus Neoadjuvant Enfortumab Vedotin Cuts Recurrence Risk 49%, Death Risk 42% Versus Standard Of Care In Muscle-Invasive Bladder Cancer Patients Ineligible For Or Refusing Cisplatin, VOLGA Phase III
Marjorie Taylor Greene Says Health Insurance Is ‘an Unaffordable Disaster’ and Republicans ‘Have Not Even Attempted to Fix It’
